Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry

Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry

Background: While neoadjuvant chemotherapy (NAC) is recommended for stage II-III triple-negative breast cancer (TNBC), its equivalence to adjuvant chemotherapy (AdjC) has been questioned based on a retrospective study using the National Cancer Database in the United States, which lacked adjustment f...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoe Taji, Hiraku Kumamaru, Yuki Kataoka, Kotaro Iijima, Hirofumi Suwa, Hiroshi Ishiguro, Naruto Taira, Takanori Ishida, Shigehira Saji
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Breast
Subjects:
Triple-negative
Breast cancer
Neoadjuvant chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625004771
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items